We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Systemic connective tissue disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The aim of our research is to discover the genetic factors that increase the risk of developing SLE using high-throughput genome sequencing technologies. This type of sequencing allows more variants to be sequenced with greater accuracy.
Using DNA together with clinical information, we can look for differences between people with SLE and those unaffected by the disease. We can use this to identify genetic differences that are more prevalent in SLE patients and then ask how these factors affect the immune system and how they influence the nature and severity of the disease.
We will collect blood from patients with SLE, who satisfy the specific criteria for disease classification, as well as healthy controls. The study will be explained to the potential participants and informed, written consent for study participation and peripheral venepuncture will be obtained.
Patients are asked to complete a short questionnaire about how they have been affected by SLE and to give a blood sample (40ml, or 8 tsp). To do this they either visit our department at Guy's or St Thomas' Hospital, or we can send a blood collection pack that the patient can take to their GP or local hospital for sample collection which will then be sent back to us.
We will use current technologies to detect genetic differences in participants’ DNA. Some of the differences will be unique to the individual. Such unique genetic differences may provide valuable insight into how the disease develops.
Some patients may be contacted, regarding other studies that we run. Participation in these studies is completely voluntary.
Though the study will represent no direct benefit to participants, we hope this research will lead to increased future understanding of disease mechanism.
Funding has been provided by the Wellcome Trust, ARUK and an ESG1 (Fp7) programme grant.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
1. Patients with severe anaemia, haemoglobin <8g/dl. 2. Pregnant women, to avoid unnecessary blood sampling.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by King's College London and funded by VERSUS ARTHRITIS; European Commission; Wellcome Trust; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 13262
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
